Nerve stimulator misses study primary endpoint

03/10/2010 | Star Tribune (Minneapolis-St. Paul, Minn.)

The FDA said Medtronic's Deep Brain Stimulation implant failed to meet its main study endpoint of reducing seizures in epilepsy patients. Medtronic said the missed study goal was due to an increase in seizure activity in one patient. An FDA panel of neurologic experts is set to meet Friday to determine if the company's data are clinically significant.

View Full Article in:

Star Tribune (Minneapolis-St. Paul, Minn.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA